Start Date
January 29, 2021
Primary Completion Date
June 30, 2023
Study Completion Date
June 30, 2023
Zurampic®
non-interventional study where patients are exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) during the normal course of clinical practice
Control group: xanthine oxidase inhibitor monotherapy
non-interventional study where patients are exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat) during the normal course of clinical practice
Lead Sponsor
AstraZeneca
INDUSTRY